About 3M Pharmaceuticals 3M Pharmaceuticals combines the agility of a small drug company with the resources of a major, multinational corporation supported by 3M's annual R&D budget of over one billion dollars. Building upon an established 3M research program in medicinal chemistry and combined with the acquisition of Riker Laboratories in 1970, 3M Pharmaceuticals is known for its immune response modifier (IRM) product platform as well as respiratory and cardiology drugs. In 1996, 3M Pharmaceuticals acquired the leading therapy for bacterial vaginosis enhancing 3M’s presence in women’s health care. 3M pioneered and introduced the portable metered dose inhaler (MDI) for treating asthma in the 1950s and introduced the first breath-actuated inhaler in 1993. Drawing on 3M’s long-standing expertise in Scotch® Tape and Post-it® Notes 3M created the innovative "drug-in-adhesive" technology for transdermal patches. For more information on 3M’s expertise in drug delivery technologies, please go to 3M Drug Delivery Systems . 3M Pharmaceuticals continues to be an innovative and reliable source for healthcare products. Contact Us with your feedback and suggestions on how we can make our web sites more useful to you.